Key clinical point: At 3 years, the BIOFLOW V trial shows a still accumulating advantage for a biodegradable ultrathin stent device over a thin stent device.
Major finding: Target lesion failure is 40% lower (8.2% vs. 13.6%) at 3 years for the Orsiro ultrathin stent relative to the Xience thin stent.
Data Source: BIOFLOW V, a randomized, multicenter, head-to-head trial comparing two drug-eluting stents.
Disclosures: Dr. Kandzari reports financial relationships with multiple device companies, including Biotronik, which funded BIOFLOW V.
Kandzari DE. CRT 2020, Late Breaking Trials session S300.